EP300 and cancer: Indeed, in Section 3, it will be explored how these interactions influence key cellular processes, such as proliferation and differentiation, and we will explore the latest advancements in the development of small-molecule inhibitors designed to disrupt CBP/p300 and β-catenin interactions, particularly in the context of cancer therapy.